 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- |||| A2B694 / A2 Biotherap
Enrollment open, Metastases: EVEREST-2: A Study to Evaluate the Safety and Efficacy of A2B694, a Logic-gated CAR T, in Subjects With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression (clinicaltrials.gov) - Feb 2, 2024
P1/2, N=230, Recruiting, Sponsor: A2 Biotherapeutics Inc.
Not yet recruiting --> Recruiting
- ||| A2B694 / A2 Biotherap
Trial completion date, Trial initiation date, Trial primary completion date, Metastases: EVEREST-2: A Study to Evaluate the Safety and Efficacy of A2B694, a Logic-gated CAR T, in Subjects With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression (clinicaltrials.gov) - Jan 1, 2024
P1/2, N=230, Not yet recruiting, Sponsor: A2 Biotherapeutics Inc.
- A2B694 / A2 Biotherap, A2B530 / A2 Biotherap
BASECAMP-1: A master prescreening study to identify patients with high-risk or metastatic solid tumors with HLA loss of heterozygosity (LOH) in preparation for Tmod CAR T-cell therapy trials (Ground Level - Exhibit Hall C - San Diego Convention Center) - Sep 27, 2023 - Abstract #SITC2023SITC_318;
P=N/A, P1/
We have identified 52 patients across sites with study-specific disease types with HLA-A*02:01 LOH; of these, 13 are currently being screened, 23 have been found ineligible, and 16 have consented. This demonstrated the feasibility of leveraging a diagnostic during routine clinical workup to identify rare, molecularly defined patients for personalized clinical studies.
- ||||| A2B694 / A2 Biotherap
New P1/2 trial, Metastases: EVEREST-2: A Study to Evaluate the Safety and Efficacy of A2B694, a Logic-gated CAR T, in Subjects With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression (clinicaltrials.gov) - Sep 25, 2023
P1/2, N=230, Not yet recruiting, Sponsor: A2 Biotherapeutics Inc.
- A2B694 / A2 Biotherap
A2B694, an autologous logic-gated cell therapy targeting mesothelin (Hall C) - Oct 6, 2022 - Abstract #SITC2022SITC_600;
P=N/A
BASECAMP-1 ( NCT04981119 ), an observational study that will identify patients with somatic HLA LOH, is currently recruiting. Eligible patients with metastatic colorectal, pancreatic, or non-small cell lung cancer will be apheresed for a future A2B694 interventional study (EVEREST-2).